{"gao_id": "GAO-20-94", "published": "2019-10-15T12:00:00Z", "released": "2019-11-14T07:00:00Z", "summary": "The Food and Drug Administration can require drug companies to establish risk-reduction strategies for drugs with serious safety concerns to help ensure their benefits outweigh their risks. For example, a company\u2019s strategy may include restricting a drug\u2019s distribution to prescribers with special training. Some strategies like these have been used to keep drugs out of the hands of companies looking to develop generic versions of...", "title": "Generic Drug Development: Stakeholders' Views of Risk Evaluation and Mitigation Strategies Differ", "topics": ["Safety concerns", "Safety", "Generic drugs", "Medicaid", "Risk assessment", "Prescription drugs", "Drugs", "Drug safety", "Health Care", "Medicare", "Hazard mitigation"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-94", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-94-highlights.pdf"}, {"title": "Full Report (38 pages)", "url": "https://www.gao.gov/assets/gao-20-94.pdf"}, {"title": "Accessible PDF (40 pages)", "url": "https://www.gao.gov/assets/710/702460.pdf"}]}